WO2013133448A1 - Sustained release oral solid preparation - Google Patents
Sustained release oral solid preparation Download PDFInfo
- Publication number
- WO2013133448A1 WO2013133448A1 PCT/JP2013/056881 JP2013056881W WO2013133448A1 WO 2013133448 A1 WO2013133448 A1 WO 2013133448A1 JP 2013056881 W JP2013056881 W JP 2013056881W WO 2013133448 A1 WO2013133448 A1 WO 2013133448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained release
- solid preparation
- oral solid
- release oral
- salt
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 193
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 193
- 238000002360 preparation method Methods 0.000 title claims abstract description 171
- 239000007787 solid Substances 0.000 title claims abstract description 140
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims abstract description 90
- 229960004372 aripiprazole Drugs 0.000 claims abstract description 90
- 150000003839 salts Chemical class 0.000 claims abstract description 87
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 66
- 239000003349 gelling agent Substances 0.000 claims abstract description 38
- 229920000161 Locust bean gum Polymers 0.000 claims abstract description 36
- 239000000711 locust bean gum Substances 0.000 claims abstract description 36
- 235000010420 locust bean gum Nutrition 0.000 claims abstract description 36
- 239000000230 xanthan gum Substances 0.000 claims abstract description 36
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 36
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 36
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 36
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 32
- 125000002091 cationic group Chemical group 0.000 claims abstract description 31
- 239000012530 fluid Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 239000008024 pharmaceutical diluent Substances 0.000 claims abstract description 22
- 230000007613 environmental effect Effects 0.000 claims abstract description 16
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 16
- 238000004132 cross linking Methods 0.000 claims abstract description 8
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 6
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 41
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 41
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 41
- 229960003943 hypromellose Drugs 0.000 claims description 38
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 28
- 230000036765 blood level Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 229910052783 alkali metal Inorganic materials 0.000 claims description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 10
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 10
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 10
- 150000001340 alkali metals Chemical class 0.000 claims description 8
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- -1 alkali metal salt Chemical class 0.000 claims description 7
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 6
- 230000002459 sustained effect Effects 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 239000003826 tablet Substances 0.000 description 66
- 239000003814 drug Substances 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- 229930195725 Mannitol Natural products 0.000 description 14
- 239000000594 mannitol Substances 0.000 description 14
- 235000010355 mannitol Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000000323 Tourette Syndrome Diseases 0.000 description 10
- 208000016620 Tourette disease Diseases 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000012239 silicon dioxide Nutrition 0.000 description 8
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 7
- 229920000926 Galactomannan Polymers 0.000 description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000004386 Erythritol Substances 0.000 description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 235000019414 erythritol Nutrition 0.000 description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 6
- 229940009714 erythritol Drugs 0.000 description 6
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- 201000000980 schizophrenia Diseases 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229920003130 hypromellose 2208 Polymers 0.000 description 5
- 229940031707 hypromellose 2208 Drugs 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 239000008019 pharmaceutical lubricant Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000008030 superplasticizer Substances 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 208000020925 Bipolar disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229920003125 hypromellose 2910 Polymers 0.000 description 3
- 229940031672 hypromellose 2910 Drugs 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 description 3
- 235000011151 potassium sulphates Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000009500 colour coating Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 150000002703 mannose derivatives Chemical group 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention relates to a sustained release oral solid preparation comprising aripiprazole or a salt thereof.
- Aripiprazole is a compound represented by the following
- Aripiprazole is used in Japan as an active ingredient of a medicinal product effective for ameliorating schizophrenia symptoms and manic symptoms in bipolar disorder.
- a medicinal product has been available from Otsuka Pharmaceutical, Co., Ltd.
- Aripiprazole and salts thereof are known as active ingredients for treating disorders of the central nervous system (CNS) associated with 5-HT IA receptor subtype, and are also known to be effective for, for example, the diseases disclosed in
- sustained release preparations have been known.
- certain moderately to poorly soluble drugs present formulation difficulties that render them inapplicable for sustained release preparations that might be suitable for, for example, relatively soluble drugs.
- Aripiprazole is very poorly soluble, and often exhibits poor pharmacokinetics when incorporated into a sustained release oral solid preparation. Therefore, it has been an urgent
- An object of the present invention is to provide a sustained release oral solid preparation comprising aripiprazole or a salt thereof as an active ingredient, and a method for producing the sustained release oral solid preparation.
- the sustained release oral solid preparation of the present invention comprises, at a specific weight ratio,
- aripiprazole or a salt thereof a gelling agent; at least one inert pharmaceutical diluent selected from the group consisting of monosaccharides, disaccharides , polyhydric alcohols, and mixtures thereof; and a pharmaceutically acceptable cationic cross-linking agent capable of crosslinking with the gelling agent and increasing the gel strength when the oral solid
- preparation of the present invention can provide sustained release of aripiprazole or a salt thereof when exposed to an environmental fluid, and is useful as, in particular, a once- weekly (QW) oral preparation.
- QW once- weekly
- the present invention has been accomplished based on these findings and further research, and includes, for example, the subject matter shown below.
- Item 1 A sustained release oral solid preparation comprising aripiprazole or a salt thereof , and a sustained
- sustained release excipient comprising
- a gelling agent comprising xanthan gum and locust bean gum
- At least one inert pharmaceutical diluent selected from the group consisting of monosaccharides, disaccharides , polyhydric alcohols, and mixtures thereof;
- a pharmaceutically acceptable cationic cross-linking agent capable of crosslinking with the gelling agent
- the ratio of the xanthan gum to the locust bean gum in the gelling agent being about 1:1 to 1:3 by weight
- the sustained release oral solid preparation according to Item 1 further comprising hypromellose, wherein the ratio of the hypromellose to the aripiprazole or a salt thereof is about 1:0.1 to 1:5, preferably about 1:0.4 to 1:2.8 by weight.
- Item 3 The sustained release oral solid preparation according to Item 1 or 2, wherein the cationic cross-linking agent is at least one salt selected from the group consisting of sulfate, chloride, borate, carbonate, phosphate, bromide, citrate, acetate, and lactate, and wherein the salt is an alkali metal salt or an alkaline earth metal salt.
- the cationic cross- linking agent comprises calcium sulfate.
- a sustained release oral solid preparation comprising aripiprazole or a salt thereof, and a sustained
- sustained release excipient comprising
- a gum comprising a combination of xanthan gum with locust bean gum
- a sugar alcohol preferably mannitol, xylitol, or erythritol, and more preferably mannitol
- an inorganic or organic salt of an alkali metal and/or an alkaline earth metal preferably at least one member selected from calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, and sodium fluoride, more preferably calcium sulfate or sodium chloride, and still more preferably calcium sulfate),
- the ratio of the xanthan gum to the locust bean gum being about 1:1 to 1:3 by weight
- the ratio of the sugar alcohol to the gum being within the range of about 1:1 to 1:2 by weight.
- Item 6 The sustained release oral solid preparation according to Item 5, further comprising hypromellose .
- Item 7 The sustained release oral solid preparation according to Item 6, wherein the sustained release oral solid preparation comprises about 45 to 85 weight% of aripiprazole or a salt thereof, and hypromellose in an amount satisfying the
- x represents a proportion (wt%) of the aripiprazole or a salt thereof, and y represents a proportion (wt%) of the
- Item 8 The sustained release oral solid preparation according to any one of Items 1 to 7, which is a tablet.
- Item 9 The sustained release oral solid preparation according to any one of Items 1 to 8, wherein at least part of a surface of the sustained release oral solid preparation is coated with an enteric material, and wherein the sustained release oral solid preparation coated with the enteric material has a weight increased by about 1 to 20 wt%, preferably about 6 wt%, relative to the sustained release oral solid preparation before coating.
- Item 10 The sustained release oral solid preparation according to Item 9, wherein the enteric material comprises a methacrylic acid copolymer.
- Item 11 The sustained release oral solid preparation according to Item 1, 2, 3, 4, 8, 9, or 10, wherein the content of the cationic cross-linking agent is about 0.5 to 20 wt% of the sustained release excipient.
- sustained release excipient comprising about 3.0 to 98.5 Wt% of a gum comprising xanthan gum and locust bean gum;
- a sugar alcohol preferably mannitol , xylitol or erythritol , and more preferably mannitol
- an inorganic or organic salt of an alkali metal and/or an alkaline earth metal preferably at least one member selected from calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride,
- the ratio of the xanthan gum to the locust bean gum being about 1:1 to 1:3 by weight
- the ratio of the sugar alcohol to the gum being within the range of about 1:1 to 1:2 by weight.
- the sustained release oral solid preparation obtained by the production method of Item 12 preferably maintains a
- therapeutically effective blood level of the aripiprazole or a salt thereof for at least 12 hours, more preferably at least about one week, up to about 2 weeks when exposed to an
- a method for producing a sustained release oral solid preparation comprising:
- a gelling agent comprising xanthan gum and locust bean gum
- the ratio of the xanthan gum to the locust bean gum being about 1:1 to 1:3 by weight; and mixing the sustained release excipient with
- aripiprazole or a salt thereof to prepare a sustained release oral solid preparation
- the sustained release oral solid preparation when exposed to an environmental fluid, the preparation maintains a therapeutically effective blood level of the
- aripiprazole or a salt thereof for at least 12 hours, preferably at least about one week, up to about 2 weeks.
- Item 14 The method for producing a sustained release oral solid preparation according to Item 12 or 13, wherein the sustained release excipient is mixed with aripiprazole or a salt thereof so that the produced sustained release oral solid preparation comprises about 45 to 85 wt% of aripiprazole or a salt thereof, and hypromellose in an amount satisfying the following inequality:
- x represents the proportion (wt%) of the aripiprazole or a salt thereof, and y represents the proportion (wt%) of the hypromellose.
- Item 15 A method for treating a central nervous system disease, comprising orally administering the sustained release oral solid preparation of any one of Items 1 to 11 to a patient suffering from a central nervous system disease.
- sustained release oral solid preparation of the present invention even when the preparation is administered at a high dose, an initial "burst" of the drug release from the sustained release oral solid preparation at the time the sustained release oral solid preparation is exposed to an aqueous solution or gastrointestinal fluid can be prevented, and an unnecessary increase in the blood level peak of the aripiprazole or a salt thereof, i.e., the active ingredient , can be suppressed.
- the effective blood level of the aripiprazole or a salt thereof can be maintained for 12 hours, more preferably 24 hours, and most preferably 1 week, up to about 2 weeks.
- the sustained release preparation of the present invention is
- the sustained release oral solid preparation of the present invention is particularly effective for Tourette's syndrome, which is a CNS disease. It is particularly preferable that the preparation of the invention contains 150 to 300 mg of aripiprazole when used for schizophrenia symptoms.
- Aripiprazole having any crystal form may be used for the preparation of the invention; however, it is most preferable that aripiprazole anhydride crystals B disclosed in Japanese Patent No. 3760264 be used. The disclosures of this patent document are incorporated herein by reference.
- Fig. 1 is a graph showing average blood level versus time profiles of aripiprazole in test subjects after
- Fig. 2 is a graph showing average blood level versus time profiles of aripiprazole in test subjects after
- Example 2 administration of the oral preparation of Example 1 after a meal in Test Example 2.
- the sustained release oral solid preparation of the present invention comprises aripiprazole or a salt thereof, and a sustained release excipient.
- the sustained release excipient comprises a gelling agent; at least one inert pharmaceutical diluent selected from the group consisting of monosaccharides, disaccharides ,
- polyhydric alcohols, and mixtures thereof and mixtures thereof; and a pharmaceutically acceptable cationic cross-linking agent capable of crosslinking with the gelling agent and increasing the gel strength when the sustained release oral solid preparation is exposed to an
- sustained release used in this specification means that the drug is released from the sustained release oral solid preparation at a controlled rate such that therapeutically beneficial blood levels (but below toxic levels) of the active ingredient is maintained over an extended period of time, e.g., providing a dosage form that can maintain the effective blood level of the drug for 12 hours or 24 hours, most preferably 1 week.
- PK pharmacokinetics
- environment fluid refers to a fluid that presents in the environment of the sustained release oral solid preparation when the sustained release oral solid preparation is taken by a subject.
- environment fluid refers to water ingested with the preparation or to a fluid secreted by digestive organs. The term may also be referred to as
- dissolution fluid includes water, an aqueous solution, saliva, gastrointestinal fluid, and the like.
- the gelling agent used in the present invention comprises xanthan gum and locust bean gum.
- Xanthan gum is a high molecular weight (>10 6 ) polysaccharide with a structure having a main chain of glucose to which side chains of mannose, glucuronic acid, and pyruvic acid are attached.
- Locust bean gum is a polysaccharide with a structure having a main chain of mannose and a side chain of galactose.
- Locust bean gum is a kind of galactomannans.
- Galactomannans are polysaccharides composed mainly of mannose and galactose.
- a combination of xanthan gum with a galactomannan can be used as a gelling agent; however, the present invention particularly uses locust bean gum among galactomannans.
- Galactomannans which have higher proportions of unsubstituted mannose regions, have been found to achieve more interaction with xanthan gum.
- Locust bean gum which has a higher ratio of mannose to galactose, as compared to other galactomannans such as guar gum and hydroxypropyl guar gum, is particularly preferred.
- the gelling agent used in the present invention may contain one or more other polysaccharides (e.g., one or more other polysaccharides (e.g., one or more other polysaccharides (e.g., one or more other polysaccharides (e.g., one or more other polysaccharides (e.g., one or more other polysaccharides (e.g., one or more other polysaccharides (e.g.
- the gelling agent used in the present invention is particularly preferably a gum comprising a combination of xanthan gum with a galactomannan.
- the ratio of the xanthan gum to the locust bean gum is about 1:1 to 1:3, and is more preferably about 1:1 to 1:2, by weight.
- the gelling agent is contained in the sustained release excipient in a proportion of preferably about 3.0 to 98.5 wt%. more preferably about 10 to 98.5 wt%, still more preferably about 30 to 70 wt%, and even more preferably about 40 to 60 wt%.
- the gelling agent is contained in the sustained release oral solid preparation in a proportion of preferably about 0.5 to 50 wt%, more preferably about 1 to 50 wt%, and still more
- the proportion of the gelling agent in the sustained release oral solid preparation is preferably about 1 to 20 wt% is preferable, more preferably about 1 to 10 wt%, and still more preferably about 1 to 5 t%.
- the ratio of the gelling agent to the aripiprazole or a salt thereof is preferably about 1:1 to 1:100, more preferably about 1:1 to 1:50, still more preferably about 1:2 to 1:30, and even more preferably about 1:5 to 1:25, by weight.
- the inert pharmaceutical diluent preferably comprises at least one pharmaceutically acceptable saccharide selected from the group consisting of monosaccharides, disaccharides ,
- polyhydric alcohols and mixtures of any of the foregoing.
- inert pharmaceutical diluents include sucrose, dextrose, lactose, microcrystalline cellulose, fructose, xylitol, sorbitol, mannitol, erythritol, maltitol, reduced palatinose, mixtures thereof, and the like.
- pharmaceutical diluents may be used singly or in a combination of two or more.
- a sugar alcohol is preferable among saccharides, with mannitol, xylitol, and erythritol being more preferable, and with mannitol being
- the ratio of the inert pharmaceutical diluent to the gelling agent is about 1:1 to 1:2 by weight.
- the inert pharmaceutical diluent is contained in the sustained release excipient in a proportion of preferably about 1.0 to 89 wt%, more preferably about 5 to 50 wt%, and still more preferably about 30 to 50 wt%.
- the inert pharmaceutical diluent is contained in the sustained release oral solid preparation in a proportion of preferably about 0.5 to 80 wt%, more preferably about 1 to 80 wt%, still more preferably about 2.0 to 10 wt%, and even more
- diluent :aripiprazole or a salt thereof is preferably about 1:3 to 1:125, more preferably about 1:3 to 1:60, still more
- sustained release excipient consisting only of the gelling agent is not sufficient to provide desired sustained release of an insoluble drug (aripiprazole or a salt thereof), nor is it sufficient to prevent an initial "burst" of drug
- sustained release oral solid preparation when the sustained release oral solid preparation is exposed to a fluid in an environment of use (environmental fluid), e.g., an aqueous solution or gastrointestinal fluid.
- a fluid in an environment of use e.g., an aqueous solution or gastrointestinal fluid.
- the gel strength of the sustained release oral solid preparation can be significantly increased.
- the cationic cross-linking agent used in the present invention is a pharmaceutically acceptable cationic cross-linking agent capable of increasing the gel strength when the sustained release oral solid preparation is exposed to an environmental fluid.
- Specific examples of the cationic cross-linking agents include salts that generate monovalent or multivalent metal cations.
- Examples of preferable salts include inorganic and organic salts of various alkali metals and/or alkaline earth metals.
- Examples of the inorganic salts include alkali metal and/or alkaline earth metal sulphates, chlorides, borates,
- organic salts include alkali metal and/or alkaline earth metal citrates, acetates, lactates, and the like.
- Sodium, potassium, etc. are preferable as the alkali metal.
- Magnesium, calcium, etc. are preferable as the alkaline earth metal.
- suitable cationic cross-linking agents include calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium
- preferable cross-linking agents are salts that generate divalent or monovalent cations.
- a preferable salt among these is calcium sulfate or sodium chloride, with calcium sulfate being
- the cationic cross-linking agents may be used singly or in a combination of two or more.
- the cationic cross-linking agents of the present invention are incorporated in an amount effective to obtain a desirable gel strength.
- the content of the cationic cross-linking agent is preferably about 0.1 to 20 wt%, more preferably about 0.5 to 20 wt%, still more preferably about 0.5 to 5.0 wt%, and even more preferably 0.5 to 2.0 wt%, of the sustained release oral solid preparation.
- the ratio of the cationic cross-linking agent to the gelling agent is adjusted according to the components of the cationic cross- linking agent and gelling agent to be specifically used. For example, the ratio thereof is preferably about 1:1 to 1:10, and more preferably about 1:2 to 1:7, by weight.
- the cationic cross-linking agent is contained in the sustained release excipient in a proportion of preferably about 0.5 to 20 wt%, more preferably about 1 to 20 wt%, and still more preferably about 5 to 15 wt%.
- the ratio of the cationic cross-linking agent to the arxpiprazole or a salt thereof is preferably about 1:10 to 1:500, more preferably about 1:10 to 1:250, still more preferably about 1:10 to 1:150, even more preferably about 1:15 to 1:110, and most preferably about 1:30 to 1:110, by weight.
- one of the most preferable examples of the sustained release excipient used in the present invention is an excipient comprising mannitol, calcium sulfate, and a gum comprising a combination of xanthan gum with locust bean gum.
- the ratio of the xanthan gum to the locust bean gum is about 1:1 to 1:3 by weight
- the ratio of the mannitol and the gum is within the range of about 1:1 to 1:2 by weight.
- sustained release oral solid preparation of the present invention further comprising hypromellose (another name of hydroxypropyl methylcellulose (HPMC)) can maintain the sustained release oral solid preparation of the present invention.
- hypromellose another name of hydroxypropyl methylcellulose (HPMC)
- the sustained release property of aripiprazole is improved; further incorporation of hypromellose into the preparation further improves the sustained release property of aripiprazole.
- the ratio of hypromellose to aripiprazole or a salt thereof is preferably about 1:0.1 to 1:10, more preferably about 1:0.1 to 1:5, and even more preferably about 1:0.4 to 1:2.8, by weight.
- Hypromellose is contained in the sustained release oral solid preparation in a proportion of preferably about 10 to 60 wt%, more preferably about 20 to 60 wt%, and still more
- the form of the sustained release oral solid preparation of the present invention is not limited. Examples thereof include a powder, a granule, a tablet, and the like, with a tablet being preferable.
- the tablet may be a coated tablet. Specifically, the tablet includes not only uncoated tablets but also coated tablets. For example, chewable tablets, oral- disintegrating tablets , etc . , are also included therein.
- the sustained release oral solid preparation of the present invention may further comprise a pharmaceutical lubricant.
- sustained release excipient may further comprise
- the pharmaceutical lubricant may be added to the components of the sustained release excipient at the time the drug is added, or in any event prior to
- Examples of pharmaceutical lubricants include generally accepted pharmaceutical lubricants such as calcium soap or magnesium soap.
- lubricants examples include magnesium stearate, sodium stearyl fumarate, and the like.
- Sodium stearyl fumarate is a particularly preferable lubricant.
- the lubricant is contained in the sustained release oral solid preparation in a proportion of preferably about 1 to
- the sustained release oral solid preparation of the present invention may further comprise a pharmaceutical
- a superplasticizer particularly reduces the contacts between crystals with high hygroscopic property to prevent aggregation and crosslinking from occurring.
- superplasticizer is therefore added for the purpose of increasing the flowability (in particular, for the purpose of increasing the flowability of a powder for tablet).
- superplasticizers include fine silica (silicon dioxide).
- the superplasticizer is contained in the sustained release oral solid preparation in a proportion of, for example, preferably about 0.1 to 2 wt%, more preferably about 0.2 to 1 wt%, and still more preferably about 0.3 to 0.7 wt%.
- the sustained release oral solid preparation of the present invention may further contain various other ingredients
- a coating may be formed on the sustained release oral solid preparation of the present invention.
- the sustained release oral solid preparation is preferably coated with an enteric material (an enteric-coated sustained release oral solid preparation) , because the effective blood level of the active ingredient , i.e., the aripiprazole or a salt thereof , can thereby be maintained for about 1 week, up to about 2 weeks.
- an enteric material an enteric-coated sustained release oral solid preparation
- a color coating may also be formed on the preparation of the active ingredient
- the proportions of the components contained in the preparation refer to the proportions relative to the sustained release oral solid preparation before the coating is formed thereon (uncoated preparation).
- the sustained release oral solid preparation is coated with an
- the proportions relative to the sustained release oral solid preparation refer to the proportions relative to the sustained release oral solid preparation before an enteric material is coated thereon (uncoated preparation).
- enteric materials an enteric coating agent
- enteric materials an enteric coating agent
- a methacrylic acid copolymer Particularly preferred is a methacrylic acid copolymer.
- a copolymer obtained by copolymer!zation using a monomer mixture comprising ethyl acrylate and methacrylic acid is preferable as a methacrylic acid copolymer.
- acrylate and methacrylic acid is preferable.
- copolymers of ethyl acrylate and methacrylic acid a copolymer obtained by copolymerization at a molar ratio of ethyl acrylate to methacrylic acid of about 2:1 to 1:2 is preferable, and a
- copolymer obtained by copolymerization at a molar ratio thereof of about 1:1 is particularly preferable.
- a commercially available product can also be used as a methacrylic acid copolymer.
- Enteric materials may be used singly or in a combination of two or more.
- the content of the enteric material is preferably about 3 to 10 wt%, and particularly preferably about 5 to 7 wt%, of the entire sustained release oral solid preparation coated with an aforementioned enteric material.
- the sustained release oral solid preparations coated with an aforementioned enteric material preferably has a weight increased by preferably about 1 to 20 wt%, more preferably about 1 to 10 wt%, still more preferably about 6 to 8 wt%, relative to the sustained release oral solid preparations before coating.
- the amount of the aripiprazole or a salt thereof contained in the sustained release oral solid preparation is preferably within the range of about 1 to 350 mg, more preferably about 1 to 250 mg, still more preferably about 1 to 200 mg, even more preferably about 20 to 150 mg. Particularly preferably, the amount of the aripiprazole or a salt thereof contained in the sustained release oral solid preparation is about 50 to 350 mg.
- sustained release excipient contained in the sustained release oral solid preparation of the present invention are dependent in part on the individual
- xanthan gum and locust bean gum properties of the xanthan gum and locust bean gum, in terms of polymer solubility, glass transition temperatures etc.; and are also dependent on the synergism between both xanthan gum and locust bean gum, and between the xanthan gum, locust bean gum and an inert pharmaceutical diluent (e.g., inert saccharide
- constituents preferably sugar alcohol
- sustained release oral solid preparation of the present invention even when the preparation is administered at a high dose, an initial "burst" of the drug release from the sustained release oral solid preparation at the time the sustained release oral solid preparation is exposed to a dissolution fluid (e.g., an aqueous solution or gastrointestinal fluid) can be prevented, and an unnecessary increase in the blood level peak of the aripiprazole or a salt thereof, i.e., the active ingredient, can be suppressed. Further, the effective blood level of the aripiprazole or a salt thereof can be
- sustained release oral solid preparation of the present invention is, but is not particularly limited to, a tablet in which an uncoated tablet containing aripiprazole or a salt thereof, a sustained release excipient, hypromellose, a superplasticizer (in
- the sustained release excipient comprises mannitol, calcium sulfate, and a gum comprising a combination of xanthan gum with locust bean gum.
- the ratio of the xanthan gum to the locust bean gum is about 1:1 to 1:3 by weight, and the ratio of the mannitol to the gum is within the range of about 1:1 to 1:2 by weight.
- this oral solid preparation is also referred to as "optimum dosage form preparation example 1").
- the proportion of hypromellose is preferably adjusted according to the proportion of aripiprazole or a salt thereof.
- the effects of the present invention can thereby be better exerted.
- the adjustment of the proportion of hypromellose is preferably performed to obtain a preparation that satisfies the target PK profile of aripiprazole for Tourette's syndrome (in particular, pediatric Tourette' s syndrome) .
- the effects of the present invention can be better exerted by adjusting the proportion of hypromellose as above.
- hypromellose when the sustained release oral solid preparation comprises aripiprazole or a salt thereof in a proportion of about 45 to 85 wt% (preferably about 50 to 80 wt%), hypromellose is preferably contained therein in a proportion satisfying the following inequality:
- x represents the proportion (wt%) of the aripiprazole or a salt thereof in the sustained release oral solid preparation
- y represents the proportion (wt%) of the hypromellose in the sustained release oral solid preparation
- the sustained release excipient is incorporated in an amount of (100 - x - y) wt% or less.
- the amount of the sustained release excipient is preferably 1 to 15 wt%, and more preferably 2 to 10 wt%, while satisfying the amount range of (100 - x - y) wt% or less.
- sustained release oral solid preparation contains aripiprazole or a salt thereof in a
- the proportion of hypromellose is preferably 27.02 to 32.02 wt%.
- sustained release oral solid preparation contains aripiprazole or a salt thereof in a proportion of about 45 to 85 wt% (preferably about 50 to 80 wt%)
- hypromellose is more preferably contained therein in a proportion satisfying the following inequality: -0.733X + 72 ⁇ y ⁇ -0.733x + 76,
- Examples of the method for producing the sustained release oral solid preparation of the present invention include a production method comprising mixing the above-mentioned sustained release excipient with aripiprazole or a salt thereof. Examples thereof also include a production method comprising preparing a sustained release excipient, and mixing the sustained release excipient with aripiprazole or a salt thereof to prepare a
- a sustained release excipient and aripiprazole or a salt thereof can be mixed according to a known method.
- a mixing method is exemplified in which a sustained release excipient and aripiprazole or a salt thereof (more
- the thus-obtained particles can be used as the sustained release oral solid preparation of the present invention.
- the thus-obtained particles can be formulated into a preparation (e.g., tablets) after a lubricant is
- Such a preparation obtained in this manner can also be preferably used as the sustained release oral solid preparation of the present invention.
- the form (dosage form) of the sustained release oral solid preparation is not particularly limited.
- the step may only comprise mixing the sustained release excipient with aripiprazole or a salt thereof to obtain a mixed composition (e.g., granular material).
- the step may comprise mixing the sustained release excipient with aripiprazole or a salt thereof to obtain a mixed composition, optionally adding a lubricant , etc. , to the composition, and forming the resulting composition into a tablet or the like.
- the step further comprises, for example, forming a coating on the tablets .
- a method comprising mixing a gelling agent, a cationic cross-linking agent, and an inert pharmaceutical diluent to obtain a sustained release excipient, adding aripiprazole or a salt thereof and hypromellose thereto, compressing the resulting mixture into tablets, and optionally enteric-coating the tablets can be exemplified.
- the combination of the gelling agent i.e., a mixture of xanthan gum and locust bean gum
- the inert diluent with or without the cationic cross-linking agent and hypromellose, provides a ready-to-use product in which a formulator need only blend the desired active drug and an optional lubricant with the excipient and then compress the mixture to form slow-release tablets .
- the combination of the cationic cross- linking agent, the gelling agent, and the inert diluent provides a ready-to-use excipient for a formulator.
- an excipient can be preferably used to release the drug in a sustained manner.
- a formulator only need blend the desired active drug, hypromellose, if necessary, and an optional lubricant with the excipient, and then compress the mixture to form slow-release tablets.
- the slow-release tablets can provide sustained release, and can thus be used as a sustained release oral solid
- the sustained release excipient may comprise a physical admix of the gum (xanthan gum and locust bean gum) , an inert pharmaceutical diluent (e.g., saccharides usable as a soluble excipient, such as sucrose, lactose, dextrose, cellulose,
- an inert pharmaceutical diluent e.g., saccharides usable as a soluble excipient, such as sucrose, lactose, dextrose, cellulose
- mannitol, xylitol, and erythritol and a cationic cross-linking agent. It is preferable to mix plain (i.e., crystalline) sucrose, lactose, dextrose , cellulose, mannitol, xylitol, erythritol, etc . , as the inert pharmaceutical diluent, with the gums and the
- the granulate form has certain advantages including the fact that it can be optimized for flow and compressibility; it can be tableted, formulated in a capsule, extruded and spheronized with an active drug to form pellets, etc.
- the sustained release excipients (in particular, pharmaceutically usable excipients) obtained, for example, in the above manner may be prepared according to any agglomeration technique to yield an acceptable excipient product.
- a moistening agent such as water, propylene glycol, glycerol, alcohol or the like is added to prepare a moistened mass.
- the moistened mass is dried.
- the dried mass is then milled with conventional equipment into granules to thereby obtain an excipient product.
- the excipient product is ready to use.
- the sustained release excipient is free-flowing and directly compressible. Accordingly, the excipient may be mixed in the desired proportion with aripiprazole or a salt thereof and optional lubricant (dry granulation). Alternatively, all or part of the excipient may be subjected to a wet granulation with aripiprazole or a salt thereof, and thereafter tableted.
- the final product to be produced is tablets, the complete mixture, in an amount sufficient to make a uniform batch of tablets, is then subjected to tableting in a conventional production-scale
- One of the limitations of direct compression as a method of tablet production is the size of the tablet. If the amount of aripiprazole or a salt thereof is high, a formulator may choose to wet-granulate aripiprazole or a salt thereof with other excipients to attain a tablet of decent size with the right compact strength. Usually, the amount of filler/binder or excipients needed in wet granulation is less than that in direct compression since the process of wet granulation contributes to some extent toward the desired physical properties of a tablet.
- the present invention is further related to a method for treating a central nervous system disease, comprising orally administering the above-described sustained release oral solid preparation to a patient.
- the central nervous system disease treated by orally administering the above-described sustained release oral solid preparation to a patient include schizophrenia symptoms, manic symptoms in bipolar disorder, and disorders of the central nervous system associated with 5-H IA receptor subtype.
- disorders of the central nervous system associated with 5-HT IA receptor subtype include the diseases disclosed in Japanese Patent No. 4178032. The disclosures of this patent document are incorporated herein by reference.
- the treatment involving the oral administration of the sustained release oral solid preparation of the present invention is effective for Tourette's syndrome. It is preferable that the sustained release oral solid preparation of the present invention is administered, for example, as a once- weekly (Q ) oral preparation, in order to improve medication compliance and QOL in pediatric patients.
- Q once- weekly
- Tourette's syndrome is a disease mainly developing in children (6 to 17 years old).
- the effective blood level can be preferably maintained for about 1 week, up to preferably about 2 weeks.
- the dosage of the above-described sustained release oral solid preparation is suitably selected depending on its usage, patient's age, sex, severity of the disease, and other conditions. In general, it is sufficient if the dose of the aripiprazole or a salt thereof , i.e., an active ingredient , is about 0.001 to 100 mg, preferably about 0.001 to 50 mg, per 1 kg of body weight per day.
- the frequency of the administration is suitably determined such that the effective blood level is
- the administration be performed once per week.
- the dosage of the above-described sustained release oral solid preparation in the treatment of Tourette's syndrome in pediatric patients is preferably administered once per week.
- the amount of aripiprazole or a salt thereof as the active ingredient is preferably about 10 to 200 mg/week, more preferably about 20 to 120 mg/week.
- Oral preparations (Tablets 1-3) were produced according to the following formulations and production processes.
- the tablets were formed using the above ingredients, and then coated with 6.5 mg of a methacrylic acid copolymer (Eudragit L30D-55).
- Silicon dioxide 0.5 wt%
- the tablets were formed using the above ingredients and then coated with 8.0 mg of a methacrylic acid copolymer (Eudragit L30D-55).
- Silicon dioxide 0.5 wt%
- Sodium stearyl fumarate 2.5 wt% The tablets were formed using the above ingredients, and then coated with 10.0 mg of a methacrylic acid copolymer (Eudragit L30D-55).
- Hypromellose 2208 is produced by Dow Wolff, and TIMERx®-M50A (Penwest Pharmaceuticals) is a sustained release excipient produced according to the method disclosed in WO 2008/045060 (corresponding to Japanese PCT
- Example 2 is hereby incorporated in the present specification by reference .
- Tablets 1 to 3 are manufactured by first adding aripiprazole, TIMERx®-M50A and Hypromellose 2208 into a high shear mixer, and dry mixing the ingredients with the main impeller at low speed and the chopper turned off.
- Water is added at a constant flow rate to the mixer with the impeller and chopper at low speed. Following the water addition, the impeller and chopper are run at high speed until the desired granulation endpoint is reached.
- the dried granulation is sized by passing it through a mill.
- the granules are added to a V-blender along with the silicon dioxide (screened through a 30-mesh sieve), and blended for a set amount of time.
- the sodium stearyl fumarate (screened through a 30-mesh sieve) is added to the V-blender, and blended for a set amount of time.
- the final blend is compressed on a tablet press to the desired weight, thickness, hardness, and friability
- the enteric film coating is applied to the tablets by first preparing the coating dispersion. Talc and water are mixed until dispersed. Triethy1 citrate is added to the talc dispersion, and mixed until dispersed. The talc dispersion is added to a Eudragit® L30D-55 dispersion (screened through 60-mesh sieve) while mixing until dispersed. The final dispersion is applied to the tablets in a coating pan until a weight gain of approximately 9.6% is reached. The coated tablets are cured in the coating pan at 35-45SC for a minimum of 2 hours.
- Fig. 2 shows changes in blood level from the time of the administration to one week after the administration.
- Test Examples 1 and 2 showed that, even after a week, the sustained release oral solid preparation of the present invention satisfied the target PK profile of aripiprazole for Tourette's syndrome (in particular, pediatric Tourette's syndrome); that is, Qua* ⁇ 150 ng/ml, Ctrough ⁇ 20 ng/ml.
- Tablets 4 to 6 were produced by first producing core tablets through Steps 1 to 6, and then coating the core tablets (enteric coating and color film coating in this order) . Tablets 4 to 6 were obtained as a result of analysis of effective formulations of the components to produce preparations exhibiting an excellent sustained-release characteristic of aripiprazole. In particular, the preparations are considered to be effective for schizophrenia.
- the amount can be changed within an appropriate range; water is completely removed during the core tablet production step or the coating step.
- Hypromellose 2910 67.00%, Titanium dioxide : 31.09%, Iron oxide yellow: 1.91%
- *3 The amount can be changed within an appropriate range; water is completely removed during the core tablet production step or the coating step.
- Hypromellose 2910 67.00%, Titanium dioxide: 31.09%, Iron oxide yellow : 1.91%
- *3 The amount can be changed within an appropriate range; water is completely removed during the core tablet production step or the coating step.
- Hypromellose 2910 67.00%, Titanium dioxide: 31.09%, Iron oxide yellow : 1.91 %
- Table 4 summarizes proportions (wt%) of aripiprazole or salts thereof, and hypromellose in the sustained release oral solid preparations (uncoated tablets) in Examples 1 to 6 (Tablets 1 to 6) .
- Fig. 3 shows a linear approximation graph based on Table
- preparation is preferably produced by ensuring the regularity.
- aripiprazole or a salt thereof.
- x represents a proportion of aripiprazole or a salt thereof (wt%) in the sustained release oral solid
- y represents a proportion of hypromellose (wt%) in the sustained release oral solid preparation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201491640A EA201491640A1 (en) | 2012-03-06 | 2013-03-06 | ORAL SOLID PREPARATIONS WITH PROLONGED DELIVERY |
CA2865882A CA2865882A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
MX2014010574A MX2014010574A (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation. |
US14/383,401 US20150037424A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
KR1020147027554A KR20140131987A (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
EP13712944.1A EP2822989A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
JP2014543382A JP2015509482A (en) | 2012-03-06 | 2013-03-06 | Long-acting oral solid preparation |
IN6939DEN2014 IN2014DN06939A (en) | 2012-03-06 | 2013-03-06 | |
AU2013228315A AU2013228315A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
CN201380013047.5A CN104159949A (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
SG11201404915SA SG11201404915SA (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
PH12014501853A PH12014501853A1 (en) | 2012-03-06 | 2014-08-15 | Sustained release oral solid preparation |
HK15101485.3A HK1200738A1 (en) | 2012-03-06 | 2015-02-10 | Sustained release oral solid preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261607291P | 2012-03-06 | 2012-03-06 | |
US61/607,291 | 2012-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013133448A1 true WO2013133448A1 (en) | 2013-09-12 |
Family
ID=48014240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/056881 WO2013133448A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
Country Status (17)
Country | Link |
---|---|
US (1) | US20150037424A1 (en) |
EP (1) | EP2822989A1 (en) |
JP (1) | JP2015509482A (en) |
KR (1) | KR20140131987A (en) |
CN (1) | CN104159949A (en) |
AR (1) | AR090245A1 (en) |
AU (1) | AU2013228315A1 (en) |
CA (1) | CA2865882A1 (en) |
CO (1) | CO7091180A2 (en) |
EA (1) | EA201491640A1 (en) |
HK (1) | HK1200738A1 (en) |
IN (1) | IN2014DN06939A (en) |
MX (1) | MX2014010574A (en) |
PH (1) | PH12014501853A1 (en) |
SG (1) | SG11201404915SA (en) |
TW (1) | TW201343201A (en) |
WO (1) | WO2013133448A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517951B2 (en) | 2012-04-23 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Injectable preparation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018174986A (en) * | 2017-04-03 | 2018-11-15 | 花王株式会社 | Absorption structure and absorbent article comprising the same |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
EP0581676A2 (en) * | 1992-07-30 | 1994-02-02 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
WO1997039050A1 (en) * | 1996-04-18 | 1997-10-23 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems - amorphous drugs |
JP3760264B2 (en) | 2001-09-25 | 2006-03-29 | 大塚製薬株式会社 | Aripiprazole hydrate, aripiprazole anhydrous crystals, methods for producing them and formulations containing them |
WO2006094083A1 (en) * | 2005-02-28 | 2006-09-08 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
JP4170032B2 (en) | 2002-07-12 | 2008-10-22 | 本多通信工業株式会社 | Optical splitter and O / E conversion connector |
JP4178032B2 (en) | 2001-01-29 | 2008-11-12 | 大塚製薬株式会社 | 5-HT1A receptor subtype agonist |
JP2010505949A (en) | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | Robust sustained release formulation |
WO2010079506A2 (en) * | 2008-06-23 | 2010-07-15 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of aripiprazole |
WO2011032882A1 (en) * | 2009-09-15 | 2011-03-24 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100126452A (en) * | 2008-02-28 | 2010-12-01 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Pharmaceutical composition for poorly soluble drugs |
-
2013
- 2013-03-05 AR ARP130100712A patent/AR090245A1/en unknown
- 2013-03-05 TW TW102107618A patent/TW201343201A/en unknown
- 2013-03-06 AU AU2013228315A patent/AU2013228315A1/en not_active Abandoned
- 2013-03-06 EP EP13712944.1A patent/EP2822989A1/en not_active Withdrawn
- 2013-03-06 JP JP2014543382A patent/JP2015509482A/en active Pending
- 2013-03-06 IN IN6939DEN2014 patent/IN2014DN06939A/en unknown
- 2013-03-06 CN CN201380013047.5A patent/CN104159949A/en active Pending
- 2013-03-06 CA CA2865882A patent/CA2865882A1/en not_active Abandoned
- 2013-03-06 EA EA201491640A patent/EA201491640A1/en unknown
- 2013-03-06 MX MX2014010574A patent/MX2014010574A/en not_active Application Discontinuation
- 2013-03-06 SG SG11201404915SA patent/SG11201404915SA/en unknown
- 2013-03-06 US US14/383,401 patent/US20150037424A1/en not_active Abandoned
- 2013-03-06 WO PCT/JP2013/056881 patent/WO2013133448A1/en active Application Filing
- 2013-03-06 KR KR1020147027554A patent/KR20140131987A/en not_active Application Discontinuation
-
2014
- 2014-08-15 PH PH12014501853A patent/PH12014501853A1/en unknown
- 2014-10-06 CO CO14220343A patent/CO7091180A2/en unknown
-
2015
- 2015-02-10 HK HK15101485.3A patent/HK1200738A1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
EP0581676A2 (en) * | 1992-07-30 | 1994-02-02 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
WO1997039050A1 (en) * | 1996-04-18 | 1997-10-23 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems - amorphous drugs |
JP4178032B2 (en) | 2001-01-29 | 2008-11-12 | 大塚製薬株式会社 | 5-HT1A receptor subtype agonist |
JP3760264B2 (en) | 2001-09-25 | 2006-03-29 | 大塚製薬株式会社 | Aripiprazole hydrate, aripiprazole anhydrous crystals, methods for producing them and formulations containing them |
JP4170032B2 (en) | 2002-07-12 | 2008-10-22 | 本多通信工業株式会社 | Optical splitter and O / E conversion connector |
WO2006094083A1 (en) * | 2005-02-28 | 2006-09-08 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
JP2010505949A (en) | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | Robust sustained release formulation |
WO2010079506A2 (en) * | 2008-06-23 | 2010-07-15 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of aripiprazole |
WO2011032882A1 (en) * | 2009-09-15 | 2011-03-24 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517951B2 (en) | 2012-04-23 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Injectable preparation |
US11097007B2 (en) | 2012-04-23 | 2021-08-24 | Otsuka Pharmaceutical Co., Ltd. | Injectable preparation |
US11638757B2 (en) | 2012-04-23 | 2023-05-02 | Otsuka Pharmaceutical Co., Ltd. | Injectable preparation |
US12016927B2 (en) | 2012-04-23 | 2024-06-25 | Otsuka Pharmaceutical Co., Ltd. | Injectable preparation |
Also Published As
Publication number | Publication date |
---|---|
PH12014501853A1 (en) | 2014-11-17 |
EA201491640A1 (en) | 2015-01-30 |
HK1200738A1 (en) | 2015-08-14 |
SG11201404915SA (en) | 2014-10-30 |
TW201343201A (en) | 2013-11-01 |
US20150037424A1 (en) | 2015-02-05 |
CO7091180A2 (en) | 2014-10-21 |
CN104159949A (en) | 2014-11-19 |
JP2015509482A (en) | 2015-03-30 |
MX2014010574A (en) | 2014-12-08 |
IN2014DN06939A (en) | 2015-04-10 |
EP2822989A1 (en) | 2015-01-14 |
CA2865882A1 (en) | 2013-09-12 |
AU2013228315A1 (en) | 2014-09-04 |
AR090245A1 (en) | 2014-10-29 |
KR20140131987A (en) | 2014-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4785847B2 (en) | Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof | |
FI118001B (en) | Once a day oral dosage form of metoprolol | |
AU675370B2 (en) | Sustained release formulations for 24 hour release of metoprolol | |
US20060088594A1 (en) | Highly compressible controlled delivery compositions of metformin | |
JPH01250314A (en) | Gradual release agent | |
KR20130030306A (en) | Pharmaceutical compositions | |
CN111840239B (en) | Pregabalin sustained release preparation | |
KR20110119714A (en) | Pharmaceutical compositions comprising phosphate-binding polymer | |
WO2006103551A1 (en) | Controlled release formulations of oxycodone | |
WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
US8951504B2 (en) | (trimethoxyphenylamino) pyrimidinyl formulations | |
CN108778281B (en) | Pyridone derivative pharmaceutical composition and preparation method thereof | |
JP2012051810A (en) | Orally disintegrable tablet and method for producing the same | |
WO2013133448A1 (en) | Sustained release oral solid preparation | |
EP1815850A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
KR20150096787A (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
EP4183771A1 (en) | Sustained-release pharmaceutical formulation of fused tricyclic gamma-amino acid derivative and preparation method therefor | |
MXPA96000024A (en) | Form of oral dosing of metoprolol one time | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13712944 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12014501853 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 234206 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2865882 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013712944 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/010574 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013228315 Country of ref document: AU Date of ref document: 20130306 Kind code of ref document: A Ref document number: 2014543382 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14383401 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20147027554 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201491640 Country of ref document: EA Ref document number: A201410834 Country of ref document: UA Ref document number: IDP00201406036 Country of ref document: ID |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014021545 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014021545 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140829 |